What Happened?
Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the stock to perform in line with the broader market, lacking a significant catalyst for a major move in either direction. The reiterated neutral stance comes with no change to the price target. The market's negative reaction may indicate that some investors were anticipating a more positive outlook or an upgrade for the biotechnology company.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Biogen? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Biogen’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 4.8% on the news that the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their Alzheimer's drug, Leqembi, for maintenance dosing. The new, more convenient formulation, which will be marketed as Leqembi Iqlik, allows for at-home administration for patients who have been on the drug for 18 months. This provides an alternative to the previous hour-long intravenous infusions. Adding to the positive momentum, Biogen, along with partner Stoke Therapeutics, presented promising data for zorevunersen at the 36th International Epilepsy Congress. The data showed durable seizure reductions in patients with Dravet syndrome, a severe form of epilepsy, supporting the drug's potential as a first-in-class disease-modifying treatment.
Biogen is down 7.8% since the beginning of the year, and at $138.32 per share, it is trading 32.5% below its 52-week high of $204.95 from September 2024. Investors who bought $1,000 worth of Biogen’s shares 5 years ago would now be looking at an investment worth $501.14.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.